Latest news with #Yaghsizian
Business Upturn
3 days ago
- Business
- Business Upturn
HIMS SECURITIES NEWS: Did Hims & Hers Health, Inc. (NYSE:HIMS) Commit Securities Fraud? Contact BFA Law by August 25 Class Action Deadline
NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sookdeo v. Hims & Hers Health, Inc., et al. , No. 25-cv-05315. A subsequent complaint alleging substantially similar claims was also filed and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al. , No. 25-cv-05321. Why was Hims & Hers Sued for Securities Fraud? Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a 'long-term collaboration' starting with the immediate sale of Novo Nordisk's popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide. As alleged, Hims & Hers touted and misrepresented to investors the nature of its partnership with Novo Nordisk, including asserting that under the terms of the agreement His & Hers could offer both Wegovy and compounded semaglutide to its customers. Hims & Hers also allegedly represented to investors that its sale of compounded semaglutide complied with FDA regulations. The Stock Declines as the Truth is Revealed On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk' and alleged that Hims & Hers 'failed to adhere to the law which prohibits mass sales of compounded drugs.' On this news, the price of Hims & Hers stock fell $22.24 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.98 per share on June 23, 2025. Click here for more information: What Can You Do? If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Wire
27-06-2025
- Business
- Business Wire
HIMS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers' top executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.). If you suffered substantial losses and wish to serve as lead plaintiff of the Hims & Hers class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform.' The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk'; and (ii) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated. The Hims & Hers class action lawsuit further alleges that on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims & Hers 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.' On this news, the price of Hims & Hers stock fell more than 34%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Hims & Hers securities during the Class Period to seek appointment as lead plaintiff in the Hims & Hers class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Hims & Hers class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Hims & Hers class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Hims & Hers class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Business Wire
26-06-2025
- Business
- Business Wire
HIMS BREAKING NEWS: A Class Action Lawsuit has been filed against Hims & Hers Health, Inc. -- Investors are Notified to Contact BFA Law to Potentially Recover Investment Losses
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. Share If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sookdeo v. Hims & Hers Health, Inc., et al., No. 25-cv-05315. A subsequent complaint alleging substantially similar claims was also filed and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al., No. 25-cv-05321. Why was Hims & Hers Sued for Securities Fraud? Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a 'long-term collaboration' starting with the immediate sale of Novo Nordisk's popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide. As alleged, Hims and Hers touted and misrepresented to investors the nature of its partnership with Novo Nordisk, including asserting that under the terms of the agreement His & Hers could offer both Wegovy and compounded semaglutide to its customers. Hims & Hers also allegedly represented to investors that its sale of compounded semaglutide complied with FDA regulations. The Stock Declines as the Truth is Revealed On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk' and alleged that Hims & Hers 'failed to adhere to the law which prohibits mass sales of compounded drugs.' On this news, the price of Hims & Hers stock fell $22.24 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.98 per share on June 23, 2025. Click here for more information: What Can You Do? If you invested in Hims and Hers you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
